A novel quantitative assessment of minimal residual disease in patients with acute myeloid leukemia carrying NPM1 (nucleophosmin) exon 12 mutations Acute myeloid leukemia (AML) is a clinically and cytogenetically heterogeneous disease in which distinct karyotype abnormalities define the different prognostic subgroups. However, almost half of AML cases show a normal karyotype.
Mutations within the NPM1 gene occur in about 60% of adult AML with normal karyotype and represent the single most frequent molecular aberration in this subgroup of patients. 1 These mutations usually occur at exon 12, coding for the COOH-terminal region, and induce most frequently a net insertion of four base pairs. Currently, more than 40 different mutations can be identified. 2 The most common subtype of mutation, type A, consisting of the duplication of the four bases TCTG, represents about 80% of adult AML cases, and another 12-15% show mutation B due to the insertion of CATG tetra nucleotide. NPM1 mutations appear to be stable and are detectable in the majority of patients at relapse. 3, 4 Therefore, NPM1 mutant allele represents a useful marker for the quantification of minimal residual disease (MRD) in AML patients. It has been suggested that quantitative analysis of MRD has a strong prognostic value in AML patients and long-term followup of the residual leukemia cells by PCR techniques showed that positive MRD status is associated with an increased risk of relapse. 5 Gorello et al. 6 reported TaqMan system for quantitative PCR using mutation-specific primers (forward or reverse) and a common probe. More recently, Chou et al. 7 published a novel TaqMan system for the absolute quantification of MRD with one common forward primer, a common probe and mutationspecific reverse primers. Scholl et al. 8 additionally introduced methodological approaches for the rapid screening of NPM1 mutations by LightCycler assays based on the FRET principle, as well as MRD analyses of the most common mutations A and B with the LightCycler, using mutation-specific primers and SYBR Green.
In this report, we describe a novel, rapid and reproducible method for monitoring disease status after treatment with TaqMan system RQ-PCR with mutation-specific minor groove binding (MGB) probes based on allelic discrimination assays. MGB probes are shorter and more specific and have shown to produce reliable results in single-nucleotide genotyping (SNP) and allelic discrimination assays. We focused on mutations A and B, which account for almost 90% of all NPM1 mutations in AML.
We have designed forward and reverse primers to match into the intron 11 and exon 12, respectively, which are common to wild type and all mutant alleles, and three short mutationspecific MGB probes. MGB probes include VIC/MGB probes for mutant A and mutant B alleles, and one FAM/MGB probe, which is specific for wild-type allele of NPM1. For design we used Assays-by-Design Service for SNP Genotyping Assays (Applied Biosystems, Foster City, CA, USA). This approach, based on allelic discrimination, appeared to be highly specific and we did not observe any cross-reactivity in clinical samples. For rapid screening of A or B mutations, we used two independent TaqMan assays involving two sets of MGB probes: FAM/wild-type probe with VIC/mutation A probe or FAM/ wild-type probe with VIC/mutation B probe. For absolute quantification of each individual allele, we used one corresponding MGB probe in separate assay.
Sequences of primers and MGB probes, and the localization within intron 11/exon 12 are shown in Table 1 and Figure 1 , respectively.
Quantitative real-time PCR was performed with the TaqMan Universal PCR Master Mix (Applied Biosystems). In every 25 ml of reaction mixture, there were 12.5 ml of 2 Â master mix, 900 nM each primer, 200 nM MGB probe and about 200 ng genomic DNA. The reaction was performed on 7300 Sequence Detector System (Applied Biosystems); the amplification protocol consisted of 10 min at 95 1C, followed by target amplification through 50 cycles of 15 s at 92 1C, and 1 min at 60 1C. For absolute quantification of NPM1 mutants, we used cloned Table 1 Sequences of real-time quantitative-PCR probes and primers 50  49  48  47  46  45  44  43  42  41  40  39  38  37  36  35  34  33  32  31  30  29  28  27  26  25   Cycle Number   24  23  22  21  20  19  18  17  16  15  14  13  12  11  10  9  8  7  6  5  4  3 Letters to the Editor plasmid containing PCR amplification product from patient DNA bearing NPM1 mutations A or B to generate standard curves. We diluted each of the mutants serially from 2 Â 10 6 to 2 Â 10 copies per reaction and found that as low as 2 Â 10 copies of mutants A or B can be reliably detected, with amplification efficiency of about 98.7% and a slope of standard curves À3.354. These data are shown in Figures 2 and 3 . The NPM1 mutation value was normalized on the number of albumin gene copies and expressed as the number of NPM1 mutations A or B copies every 10 6 genomic equivalents according to Chiu et al.
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The assays for mutations A and B were highly specific, as a background, resulting from wild-type genomic DNA, was not observed.
Sensitivity of the assay was tested using 10-fold serial dilutions of genomic DNA, which had been obtained from an NPM1-mutated patient diagnosed in DNA pool from the peripheral blood leukocytes of six healthy donors. At least 10 À4 sensitivity was reached in all cases and this sensitivity was sufficient for the detection of MRD. Furthermore, the sensitivity of the assay was tested in a 10-fold serial dilution of plasmid with type A mutation, type B mutation and wild-type NPM1 sequences, respectively. Maximal reproducible sensitivity was 2 Â 10 plasmid molecules.
The kinetics of changes of mutant signal in two representative patients with mutation A and one patient with mutation B at the time of diagnosis, after induction therapy, and during follow-up is shown in Figure 4 .
Published data indicate that the possibility to quantitatively monitor NPM1 mutations in AML patients with normal karyotype may represent a clinically relevant approach. Unlike previously published methods with mutation-specific primers (forward or reverse) and a common TaqMan probe, we propose a highly sensitive and reproducible approach with mutationspecific probe with minor groove binder (MGB) at the 3 0 end that could be used for the long-term follow-up of MRD. It has been determined that mutations A and B represent more than 90% of all NPM1 mutations in AML, and thus our method will undoubtedly cover vast majority of the patients. Nevertheless, follow-up of other minor mutations will require design of different probes that increase the overall cost of our method.
From our experience, however, the higher cost of our new method is well compensated by increased quality of data obtained.
As such, our method offers an alternative to the standard routine laboratory evaluation. In addition, we suggest that MGB probes could also be used for the genotyping of the single-nucleotide polymorphisms, representing an efficient approach to the specific detection of NPM1 mutations without as '5qÀ syndrome' and required only the presence of an isolated del(5q) and less than 5% bone marrow blasts. This definition was primarily based on several studies [2] [3] [4] that showed the adverse prognostic impact of blast count in peripheral blood or bone marrow.
However, the WHO classification did not address two issues: first, the prototypic clinical and pathologic '5qÀ features,' which are not a prerequisite in the WHO diagnostic criteria, are frequently absent in cases that fulfill the WHO definition of '5qÀ syndrome'. The prognostic significance of the prototypic '5qÀ features' is unclear. Second, the prognostic impact of dysgranulopoiesis in the 5qÀ syndrome was not addressed. Both issues are frequently encountered in clinical practice but have remained unanswered in the literature. 
